ImetelChat

The 8-k looks all cheerful and rosy. So is there competition out there that we don't know about or are underestimating? Otherwise, the PPS is nuts.

Rizzo was my guess too. It almost sounds like paying folks to keep us in their good thoughts and actions.

Oh, now I remember. Made absolutely no sense to me.

I can't understand who the exemptions are for the not employed folks in section 2. Can anyone help me understand? a) Eligibility for Stock Awards. Stock Awards may be granted only to persons who are Employees described in Section 1(a), where the Stock Award is an inducement material to the individua...

My now much flawed formerly perfect memory is that the MM data was lackluster at best. If it had been exciting, I would think there would have been more to come.

Great find of a great article, LWS!

Might it follow that underreporting of disease incidence would correlate with undertreatment of the disease? Therefore, income is not greater than the projection for the reported incident rate?

Dare we add the wildcat- buyout

Great job, Kmall and others. Good to know of a UK presence.

I thought there would be a price jump with the Friday news. However, it often is the case there is a day or two lag for investors to get the information. Even more so during the Holidays?

Just to clarify, European review is this coming Friday, 12/13 and if the panel recommends approval, it would be up to two months before final approval is given or denied?

Is Keros a threat to Geron with the their product and now collaboration with Takeda?

We can all be thankful for Geron and the blessings it brings to patients and to investors!

Poseida Therapeutics, Inc. (NASDAQ: PSTX) shares closed up 228% at $9.38 after it announced that it has entered into a merger agreement to be acquired by Roche Holdings, Inc. (OTC: RHHBY) for $9.00 per share in cash, with a non-tradeable CVR offering up to $4.00 per share contingent on milestone ach...

NEW YORK (Reuters) - Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for three drugs, 1-1/2 months after a federal judge abruptly dismissed an earlier version of the case. The lawsuit accused Bristol My...

Offered compensation is determined based on market data, internal equity, and an applicant’s relevant skills, experience, and educational background. The salary ranges displayed below are only for those who, if selected for the role, will perform work in the specific locations listed. Please note th...

Glad to hear you are not negative. The following remarks had me thinking you might be. No need to get defensive. Jayfish Re: 2.5 M options is hallota options Post by KTArsenal » Wed Nov 13, 2024 10:38 pm What kinda timeframe are we comfortable with this go around? 2026 isn’t too far off. Are we hang...

I believe there have been three reports today of institutions recently becoming large stakeholders. That has got to be a good sign.

Some negative moods here. What about ASH presentations upcoming? What about various European approvals upcoming? What about some study results upcoming? Seems to me there is some hope on the fairly immediate horizon.

If Geron is going to go it alone, it would seem they need another product.